Opioid ligands with mixed μ/δ opioid receptor interactions: An emerging approach to novel analgesics

AAPS Journal

Volumn 8, Issue 1, 2006, Pages

  Ananthan, Subramaniam ^a  

^a SOUTHERN RESEARCH INSTITUTE   (United States)

Author keywords

Analgesics; Mixed Mu agonist Delta antagonists; Mixed Mu Delta agonists; Nonpeptides; Opioid ligands; Peptides

Indexed keywords

14 ETHOXYMETOPON DERIVATIVE; 3 HYDROXY 4 METHOXYINDOLOMORPHINAN DERIVATIVE; 4 [ALPHA (4 ALLYL 2,5 DIMETHYL 1 PIPERAZINYL) 3 HYDROXYBENZYL] N,N DIETHYLBENZAMIDE; 4 [ALPHA (4 ALLYL 2,5 DIMETHYL 1 PIPERAZINYL) 3 METHOXYBENZYL] N,N DIETHYLBENZAMIDE; 7 AMINONALTRINDOLE; 7 PHENOXYNALTRINDOLE; ALFENTANIL; ANALGESIC AGENT; ANTISENSE OLIGONUCLEOTIDE; BETA CASOMORPHINE 5; BIPHALIN; DELTA OPIATE RECEPTOR; DELTA OPIATE RECEPTOR AGONIST; DELTA OPIATE RECEPTOR ANTAGONIST; ENDOMORPHIN 2; ETORPHINE; FENTANYL; HYDROMORPHONE; LEUCINE ENKEPHALIN; MORPHINAN DERIVATIVE; MORPHINE; MU OPIATE RECEPTOR; MU OPIATE RECEPTOR AGONIST; MU OPIATE RECEPTOR ANTAGONIST; NALOXONE; NALTRINDOLE; OPIATE; OXYMORPHONE; TYROSYL DEXTRO ARGINYLPHENYLALANYLLYSINAMIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANALGESIC ACTIVITY; CHEMICAL ANALYSIS; CONSTIPATION; DISEASE SEVERITY; DNA MODIFICATION; DRUG DEPENDENCE; DRUG EFFICACY; DRUG MECHANISM; DRUG PENETRATION; DRUG POTENTIATION; DRUG TOLERANCE; DRUG USE; HUMAN; MOLECULAR INTERACTION; MUSCLE RIGIDITY; NONHUMAN; PAIN; RESPIRATION DEPRESSION; REVIEW; SEIZURE;

ANALGESICS, OPIOID; ANIMALS; DRUGS, INVESTIGATIONAL; HUMANS; LIGANDS; OPIOID PEPTIDES; RECEPTORS, OPIOID, DELTA; RECEPTORS, OPIOID, MU; TECHNOLOGY, PHARMACEUTICAL;

EID: 33645070773     PISSN: 15507416     EISSN: None     Source Type: Journal    
DOI: 10.1208/aapsj080114     Document Type: Review

References (69)

1. Aldrich JV, Vigil-Cruz SC. Narcotic analgesics. In: Abraham DJ, ed. Burger's Medicinal Chemistry and Drug Discovery. Vol 6. New York, NY: John Wiley & Sons; 2003:329-481.
2. Friderichs E. Opioids. In: Buschmann H, Christoph T, Friderichs E, Maul C, Sundermann B, eds. Analgesics, From Chemistry and Pharmacology to Clinical Application. Weinheim, Germany: Wiley-VCH; 2002:127-150.
3. Rapaka RS, Porreca F. Development of delta opioid peptides as nonaddicting analgesics. Pharm Res. 1991;8:1-8.
4. Traynor JR, Elliott J. δ-Opioid receptor subtypes and cross-talk with μ-receptors. Trends Pharmacol Sci. 1993;14:84-86.
5. Rothman RB, Holaday JW, Porreca F. Allosteric coupling among opioid receptors: evidence for an opioid receptor complex. In: Herz A, Akil H, Simon EJ, eds. Handbook of Experimental Pharmacology: Opioids I. Vol 104. Berlin, Germany: Springer-Verlag; 1993:217-237.
6. Jordan BA, Cvejic S, Devi LA. Opioids and their complicated receptor complexes. Neuropsychopharmacology. 2000;23:S5-S18.
7. Egan TM, North RA. Both mu and delta opiate receptors exist on the same neuron. Science. 1981;214:923-924.
8. Gomes I, Jordan BA, Gupta A, Trapaidze N, Nagy V, Devi LA. Heterodimerization of mu and delta opioid receptors: a role in opiate synergy. J Neurosci. 2000;20:RC110.
9. George SR, Fan T, Xie Z, et al. Oligomerization of mu- and delta-opioid receptors. Generation of novel functional properties. J Biol Chem. 2000;275:26128-26135.
10. Levac BA, O'Dowd BF, George SR. Oligomerization of opioid receptors: generation of novel signaling units. Curr Opin Pharmacol. 2002;2:76-81.
11. Fan T, Varghese G, Nguyen T, Tse R, O'Dowd BF, George SR. A role for the distal carboxyl tails in generating the novel pharmacology and G protein activation profile of mu and delta opioid receptor hetero-oligomers. J Biol Chem. 2005;280:38478-38488.
12. Kieffer BL. Opioids: first lessons from knockout mice. Trends Pharmacol Sci. 1999;20:19-26.
13. Vaught JL, Takemori AE. Differential effects of leucine and methionine enkephalin on morphine-induced analgesia, acute tolerance and dependence. J Pharmacol Exp Ther. 1979;208:86-90.
14. Horan P, Tallarida RJ, Haaseth RC, Matsunaga TO, Hruby VJ, Porreca F. Antinociceptive interactions of opioid delta receptor agonists with morphine in mice: supra- and sub-additivity. Life Sci. 1992;50:1535-1541.
15. He L, Lee NM. Delta opioid receptor enhancement of mu opioid receptor-induced antinociception in spinal cord. J Pharmacol Exp Ther. 1998;285:1181-1186.
16. Porreca F, Takemori AE, Sultana M, Portoghese PS, Bowen WD, Mosberg HI. Modulation of mu-mediated antinociception in the mouse involves opioid delta-2 receptors. J Pharmacol Exp Ther. 1992;263:147-152.
17. Martin NA, Prather PL. Interaction of co-expressed mu- and delta-opioid receptors in transfected rat pituitary GH(3) cells. Mol Pharmacol. 2001;59:774-783.
18. Cahill CM, Morinville A, Lee MC, Vincent JP, Collier B, Beaudet A. Prolonged morphine treatment targets delta opioid receptors to neuronal plasma membranes and enhances delta-mediated antinociception. J Neurosci. 2001;21:7598-7607.
19. Coop A, Rice KC. Role of delta-opioid receptors in biological processes. Drug News Perspect. 2000;13:481-487.
20. Bishop MJ, Garrido DM, Boswell GE, et al. 3-(alphaR)-alpha-((2S,5R)-4- allyl-2,5-dimethyl-1-piperazinyl)-3-hydroxyben zyl)-N-alkyl-N- arylbenzamides: potent, non-peptidic agonists of both the mu and delta opioid receptors. J Med Chem. 2003;46:623-633.
21. Lipkowski AW, Konecka AM, Sroczynska I. Double-enkephalins-synthesis, activity on guinea-pig ileum, and analgesic effect. Peptides. 1982;3:697-700.
22. Horan PJ, Mattia A, Bilsky EJ, et al. Antinociceptive profile of biphalin, a dimeric enkephalin analog. J Pharmacol Exp Ther. 1993;265:1446-1454.
23. Silbert BS, Lipkowski AW, Cepeda MS, Szyfelbein SK, Osgood PF, Carr DB. Analgesic activity of a novel bivalent opioid peptide compared to morphine via different routes of administration. Agents Actions. 1991;33:382-387.
24. Yamazaki M, Suzuki T, Narita M, Lipkowski AW. The opioid peptide analogue biphalin induces less physical dependence than morphine. Life Sci. 2001;69:1023-1028.
25. Abbruscato TJ, Thomas SA, Hruby VJ, Davis TP. Brain and spinal cord distribution of biphalin: correlation with opioid receptor density and mechanism of CNS entry. J Neurochem. 1997;69:1236-1245.
26. Mollica A, Davis P, Ma SW, Porreca F, Lai J, Hruby VJ. Synthesis and biological activity of the first cyclic biphalin analogues. Bioorg Med Chem Lett. 2006;16:367-372.
27. Bryant SD, Jinsmaa Y, Salvadori S, Okada Y, Lazarus LH. Dmt and opioid peptides: a potent alliance. Biopolymers. 2003;71:86-102.
28. Balboni G, Guerrini R, Salvadori S, et al. Evaluation of the Dmt-Tic pharmacophore: conversion of a potent delta-opioid receptor antagonist into a potent delta agonist and ligands with mixed properties. J Med Chem. 2002;45:713-720.
29. Okada Y, Fujita Y, Motoyama T, et al. Structural studies of [2′,6′-dimethyl-L-tyrosine1]endomorphin-2 analogues: enhanced activity and cis orientation of the Dmt-Pro amide bond. Bioorg Med Chem. 2003;11:1983-1994.
30. Fujita Y, Tsuda Y, Li T, et al. Development of potent bifunctional endomorphin-2 analogues with mixed mu-/delta-opioid agonist and delta-opioid antagonist properties. J Med Chem. 2004;47:3591-3599.
31. Balboni G, Cocco MT, Salvadori S, et al. From the potent and selective mu opioid receptor agonist H-Dmt-D-Arg-Phe-Lys-NH(2) to the potent delta antagonist H-Dmt-Tic-Phe-Lys(Z)-OH. J Med Chem. 2005;48:5608-5611.
32. Calderon SN, Coop A. SNC 80 and related delta opioid agonists. Curr Pharm Des. 2004;10:733-742.
33. Eguchi M. Recent advances in selective opioid receptor agonists and antagonists. Med Res Rev. 2004;24:182-212.
34. O'Neill SJ, Collins MA, Pettit HO, McNutt RW, Chang KJ. Antagonistic modulation between the delta opioid agonist BW373U86 and the mu opioid agonist fentanyl in mice. J Pharmacol Exp Ther. 1997;282:271-277.
35. Lee PH, McNutt RW, Chang KJ. A nonpeptidic delta opioid receptor agonist, BW373U86, attenuates the development and expression of morphine abstinence precipitated by naloxone in rat. J Pharmacol Exp Ther. 1993;267:883-887.
36. Su YF, McNutt RW, Chang KJ. Delta-opioid ligands reverse alfentanil-induced respiratory depression but not antinociception. J Pharmacol Exp Ther. 1998;287:815-823.
37. Gengo PJ, Pettit HO, O'Neill SJ, et al. DPI-3290 [(+)-3-((alpha-R)-alpha- ((2S,5R)-4-allyl-2,5-dimethyl-1-piperazinyl)-3-hydroxybenzyl)-N- (3-fluorophenyl)-N-methylbenzamide]. I. A mixed opioid agonist with potent antinociceptive activity. J Pharmacol Exp Ther. 2003;307:1221-1226.
38. Gengo PJ, Pettit HO, O'Neill SJ, Su YF, McNutt R, Chang KJ. DPI-3290 [(+)-3-((alpha-R)-alpha-((2S,5R)-4-Allyl-2,5-dimethyl-1-piperazinyl)-3- hydroxybenzyl)-N-(3-fluorophenyl)-N- methylbenzamide]. II. A mixed opioid agonist with potent antinociceptive activity and limited effects on respiratory function. J Pharmacol Exp Ther. 2003;307:1227-1233.
39. Lattanzi R, Spetea M, Schullner F, et al. Synthesis and biological evaluation of 14-alkoxymorphinans. 22.(1) Influence of the 14-alkoxy group and the substitution in position 5 in 14-alkoxymorphinan-6-ones on in vitro and in vivo activities. J Med Chem. 2005;48:3372-3378.
40. Grundt P, Martinez-Bermejo F, Lewis JW, Husbands SM. Opioid binding and in vitro profiles of a series of 4-hydroxy-3- methoxyindolomorphinans. Transformation of a delta-selective ligand into a high affinity kappa-selective ligand by introduction of a 5, 14-substituted bridge. J Med Chem. 2003;46:3174-3177.
41. Grundt P, Jales AR, Traynor JR, Lewis JW, Husbands SM. 14-amino, 14-alkylamino, and 14-acylamino analogs of oxymorphindole. Differential effects on opioid receptor binding and functional profiles. J Med Chem. 2003;46:1563-1566.
42. Abdelhamid EE, Sultana M, Portoghese PS, Takemori AE. Selective blockage of delta opioid receptors prevents the development of morphine tolerance and dependence in mice. J Pharmacol Exp Ther. 1991;258:299-303.
43. Hepburn MJ, Little PJ, Gingras J, Kuhn CM. Differential effects of naltrindole on morphine-induced tolerance and physical dependence in rats. J Pharmacol Exp Ther. 1997;281:1350-1356.
44. Fundytus ME, Schiller PW, Shapiro M, Weltrowska G, Coderre TJ. Attenuation of morphine tolerance and dependence with the highly selective delta-opioid receptor antagonist TIPP[psi]. Eur J Pharmacol. 1995;286:105-108.
45. Kest B, Lee CE, McLemore GL, Inturrisi CE. An antisense oligodeoxynucleotide to the delta opioid receptor (DOR-1) inhibits morphine tolerance and acute dependence in mice. Brain Res Bull. 1996;39:185-188.
46. Suzuki T, Ikeda H, Tsuji M, Misawa M, Narita M, Tseng LF. Antisense oligodeoxynucleotide to delta opioid receptors attenuates morphine dependence in mice. Life Sci. 1997;61:PL165-PL170.
47. Sanchez-Blazquez P, Garcia-Espana A, Garzon J. Antisense oligodeoxynucleotides to opioid mu and delta receptors reduced morphine dependence in mice: role of delta-2 opioid receptors. J Pharmacol Exp Ther. 1997;280:1423-1431.
48. Zhu Y, King MA, Schuller AG, et al. Retention of supraspinal delta-like analgesia and loss of morphine tolerance in delta opioid receptor knockout mice. Neuron. 1999;24:243-252.
49. Roy S, Guo X, Kelschenbach J, Liu Y, Loh HH. In vivo activation of a mutant mu-opioid receptor by naltrexone produces a potent analgesic effect but no tolerance: role of mu-receptor activation and delta-receptor blockade in morphine tolerance. J Neurosci. 2005;25:3229-3233.
50. Freye E, Latasch L, Portoghese PS. The delta receptor is involved in sufentanil-induced respiratory depression-opioid subreceptors mediate different effects. Eur J Anaesthesiol. 1992;9:457-462.
51. Foxx-Orenstein AE, Jin JG, Grider JR. 5-HT4 receptor agonists and delta-opioid receptor antagonists act synergistically to stimulate colonic propulsion. Am J Physiol. 1998;275:G979-G983.
52. Schmidt R, Vogel D, Mrestani-Klaus C, et al. Cyclic beta-casomorphin analogues with mixed mu agonist/delta antagonist properties: synthesis, pharmacological characterization, and conformational aspects. J Med Chem. 1994;37:1136-1144.
53. Schiller PW, Fundytus ME, Merovitz L, et al. The opioid mu agonist/delta antagonist DIPP-NH(2)[Psi] produces a potent analgesic effect, no physical dependence, and less tolerance than morphine in rats. J Med Chem. 1999;42:3520-3526.
54. Weltrowska G, Lemieux C, Chung NN, Schiller PW. A chimeric opioid peptide with mixed mu agonist/delta antagonist properties. J Pept Res. 2004;63:63-68.
55. Santagada V, Balboni G, Caliendo G, et al. Assessment of substitution in the second pharmacophore of Dmt-Tic analogues. Bioorg Med Chem Lett. 2000;10:2745-2748.
56. Salvadori S, Guerrini R, Balboni G, et al. Further studies on the Dmt-Tic pharmacophore: hydrophobic substituents at the C-terminus endow delta antagonists to manifest mu agonism or mu antagonism. J Med Chem. 1999;42:5010-5019.
57. Balboni G, Salvadori S, Guerrini R, et al. Potent delta-opioid receptor agonists containing the Dmt-Tic pharmacophore. J Med Chem. 2002;45:5556-5563.
58. Ananthan S, Johnson CA, Carter RL, et al. Synthesis, opioid receptor binding, and bioassay of naltrindole analogues substituted in the indolic benzene moiety. J Med Chem. 1998;41:2872-2881.
59. Ananthan S 3rd, Kezar HS 3rd, Carter RL, et al. Synthesis, opioid receptor binding, and biological activities of naltrexone-derived pyrido- and pyrimidomorphinans. J Med Chem. 1999;42:3527-3538.
60. Wells JL, Bartlett JL, Ananthan S, Bilsky EJ. In vivo pharmacological characterization of SoRI 9409, a nonpeptidic opioid mu-agonist/ delta-antagonist that produces limited antinociceptive tolerance and attenuates morphine physical dependence. J Pharmacol Exp Ther. 2001;297:597-605.
61. Xu H, Lu YF, Rice KC, Ananthan S, Rothman RB. SoRI 9409, a nonpeptide opioid mu receptor agonist/delta receptor antagonist, fails to stimulate [35S]-GTP-gamma-S binding at cloned opioid receptors. Brain Res Bull. 2001;55:507-511.
62. Ananthan S, Khare NK, Saini SK, et al. Identification of opioid ligands possessing mixed mu agonist/delta antagonist activity among pyridomorphinans derived from naloxone, oxymorphone, and hydromorphone. J Med Chem. 2004;47:1400-1412.
63. Srivastava SK, Husbands SM, Aceto MD, Miller CN, Traynor JR, Lewis JW. 4′-Arylpyrrolomorphinans: effect of a pyrrolo-N-benzyl substituent in enhancing delta-opioid antagonist activity. J Med Chem. 2002; 45:537-540.
64. Portoghese PS. Bivalent ligands and the message-address concept in the design of selective opioid receptor antagonists. Trends Pharmacol Sci. 1989;10:230-235.
65. Portoghese PS, Edward E. Smissman-Bristol-Myers Squibb Award Address. The role of concepts in structure-activity relationship studies of opioid ligands. J Med Chem. 1992;35:1927-1937.
66. Portoghese PS. From models to molecules: opioid receptor dimers, bivalent ligands, and selective opioid receptor probes. J Med Chem. 2001;44:2259-2269.
67. Daniels DJ, Kulkarni A, Xie Z, Bhushan RG, Portoghese PS. A bivalent ligand (KDAN-18) containing delta-antagonist and kappa-agonist pharmacophores bridges delta2 and kappal opioid receptor phenotypes. J Med Chem. 2005;48:1713-1716.
68. Lenard NR, Moore JB, Daniels DJ, Portoghese PS, Roerig SC. Bivalent Ligands With Mu Agonist and Delta Antagonist Pharmacophores: Spacer Length Dependence of Tolerance and Physical Dependence Suggests Associated Mu and Delta Receptors [abstract]. Neuroscience [Society for Neuroscience, Abstract Viewer and Itinerary Planner]. 2004: Abstract 406.10.
69. Daniels DJ, Lenard NR, Etienne CL, et al. Opioid-induced tolerance and dependence in mice is modulated by the distance between pharmacopores in a bivalent ligand series. Proc Natl Acad Sci USA. 2005;102:19208-19213.